Template:Serotonin syndrome vs neuroleptic malignant syndrome: Difference between revisions
Neil.m.young (talk | contribs) No edit summary |
|||
| Line 2: | Line 2: | ||
*History of a new serotonergic drug or a dose increase of a serotonergic drug are helpful | *History of a new serotonergic drug or a dose increase of a serotonergic drug are helpful | ||
*Serotonin syndrome is usually much more acute in onset than NMS which may develop over days or weeks | *Serotonin syndrome is usually much more acute in onset than NMS which may develop over days or weeks | ||
*Presence of ‘lead pipe’ rigidity is typical of NMS, while | *Presence of ‘lead pipe’ rigidity is typical of NMS, while serotonin syndrome typically manifests with tremor and hyperreflexia | ||
*Elevations in CK, LFTs, and WBC, coupled with a low iron level, distinguishes NMS from serotonin syndrome among patients taking neuroleptic and serotonin agonist medications simultaneously | *Elevations in CK, LFTs, and WBC, coupled with a low iron level, distinguishes NMS from serotonin syndrome among patients taking both neuroleptic and serotonin agonist medications simultaneously | ||
Latest revision as of 04:33, 13 February 2017
Serotonin syndrome vs Neuroleptic malignant syndrome
- History of a new serotonergic drug or a dose increase of a serotonergic drug are helpful
- Serotonin syndrome is usually much more acute in onset than NMS which may develop over days or weeks
- Presence of ‘lead pipe’ rigidity is typical of NMS, while serotonin syndrome typically manifests with tremor and hyperreflexia
- Elevations in CK, LFTs, and WBC, coupled with a low iron level, distinguishes NMS from serotonin syndrome among patients taking both neuroleptic and serotonin agonist medications simultaneously